Next Article in Journal
Inventory of the Secondary Metabolite Biosynthetic Potential of Members within the Terminal Clade of the Fusarium solani Species Complex
Previous Article in Journal
The Extracellular Lipopeptides and Volatile Organic Compounds of Bacillus subtilis DHA41 Display Broad-Spectrum Antifungal Activity against Soil-Borne Phytopathogenic Fungi
Previous Article in Special Issue
Iron Starvation Induces Ferricrocin Production and the Reductive Iron Acquisition System in the Chromoblastomycosis Agent Cladophialophora carrionii
 
 
Review
Peer-Review Record

Candida parapsilosis sensu stricto Antifungal Resistance Mechanisms and Associated Epidemiology

J. Fungi 2023, 9(8), 798; https://doi.org/10.3390/jof9080798
by Iacopo Franconi 1, Cosmeri Rizzato 1, Noemi Poma 2, Arianna Tavanti 2 and Antonella Lupetti 1,*
Reviewer 1:
Reviewer 2:
J. Fungi 2023, 9(8), 798; https://doi.org/10.3390/jof9080798
Submission received: 5 June 2023 / Revised: 18 July 2023 / Accepted: 25 July 2023 / Published: 28 July 2023
(This article belongs to the Special Issue Molecular Diagnosis, Genetics and Evolution of Human Pathogenic Fungi)

Round 1

Reviewer 1 Report

The authors presented an all-embracing review of the resistance mechanisms in Candida parapsilosis. The references are up-to-date and sufficient.

Author Response

We thank the Reviewer for her/his kind appreciation.

Reviewer 2 Report

General comments

The MS is interesting and useful for the readers of Journal of Fungi. The Authors should be mention that the MS discuss mainly the C. parapsilosis sensu stricto. However, when appropriate the genetically strongly related C. orthopsilosis or C. metapsilosis should be mention as well (MIC values, resistance mechanism, etc).

 

Specific comments

Page 2. Lines 46-63. The sentences sometimes were complicated.

Page 2. Lines 68-71 and 75-79. For clinical resistance and persistent isolation of the pathogen from the patients are frequently originated due to the ability of the pathogen producing biofilm and the low drug concentration in the infected body sites.

Page 9. It would be interesting data from isavuconazole regarding the azole resistance.

Page 8. Rezafungin was approved as well to treat severe fungal infections some month ago, thus data from rezafungin may improve the quality of the MS.

Page 9. Lines 353-369. Though this in vitro phenomenon is interesting, its clinical relevance is questionable.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

The changes looks good.

Back to TopTop